Kalos Therapeutics is Featured Presenter at Biotech Showcase™ 2015

Share this news:

The cancer “Super Drug” company Kalos will present at Bio Showcase 2015, Monday Morning in the Hearst room 9:00 AM. The company will present the latest in drug development AND THEIR First Generation Peptide - an 8 AA for the treatment of Pancreatic, and Ovarian Cancers.

Kalos Therapeutics, Inc announced today that it’s CEO, George Colberg will be presenting at the Biotech Showcase™ 2015 Conference being held in San Francisco, CA.

The cancer “Super Drug” company Kalos will present at Bio Showcase 2015, Monday Morning in the Hearst room 9:00 AM. The company will  present the latest in drug development AND THEIR First Generation Peptide - an 8 AA for the treatment of Pancreatic, and Ovarian Cancers. The company will be available to discuss licensing and collaborative agreements with their pipeline that will include Wet AMD drug and multiple Animal Health products.

Kalos Therapeutics is well regarded in the pharmaceutical / biotech world as recruiting the best of the best to develop their patented drugs and unique delivery systems. Having world class team members such as Stand Up To Cancer dream team leader Dr. Daniel Von Hoff and Pfizer’s former senior research scientist Dr. Michael Kozlowski have allowed for massive advancement in cancer drug development. As part of Kalos’ strategy to “think outside the box”

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

About Kalos Therapeutics:
Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyper proliferative disorders.

More information can be found on Kalos' web site at http://www.kalostherapeutics.com

About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. For more information please visit www.ebdgroup.com or follow EBD Group on Twitter at twitter.com/ebdgroup.

Contact Info:
Name: Kalos Therapeutics
Email: Send Email
Organization: Kalos Therapeutics
Address: 4370 La Jolla Village Drive: Suite #400
Phone: 858-385-1290
Website: http://www.kalostherapeutics.com

Release ID: 71770

CONTACT ISSUER
Name: Kalos Therapeutics
Email: Send Email
Organization: Kalos Therapeutics
Address: 4370 La Jolla Village Drive: Suite #400
SUBSCRIBE FOR MORE